PHARMA FAKTEN announces multiple health initiatives for 2025-2026
PHARMA FAKTEN has unveiled a series of health initiatives scheduled to launch from 2025 through 2026, addressing key areas from rare diseases to pharmaceutical digitalization.
PHARMA FAKTEN has announced multiple new health initiatives set to commence in 2025 and continue through 2026. These initiatives cover a broad spectrum of critical health issues, including hospital care, research, and patient-focused advancements.
A significant portion of the planned work targets the development of treatments for rare diseases and the introduction of advanced therapy medicinal products (ATMPs). The company is also increasing its focus on pediatric medicines, alongside dedicated research efforts in oncology, diabetes, and cardiovascular conditions.
Further initiatives will address challenges such as antimicrobial resistance and the health impacts of the climate crisis. The digitalization of healthcare, including its role in shaping future pharmaceutical jobs, is also a key focus for the upcoming period.
PHARMA FAKTEN is committed to enhancing patient centricity and exploring new business models within the pharmaceutical sector. The overarching aim of these efforts is to improve efficiency and foster innovation across various domains of medical science and healthcare delivery.